Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 4,158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: STD Clear all
Terminated Phase 4 Interventional

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

NCT00781287
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3-drug anti-HIV therapy, Raltegravir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Not applicable Interventional

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

NCT00002304
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Ketoconazole, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 1Phase 2 Interventional

CCR5-modified CD4+ T Cells for HIV Infection

NCT03666871
View directory record Official record
Conditions
HIV Infections
Interventions
SB-728-T, Expanded unmodified autologous CD4+ T cells
Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

NCT02778204
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 3 Days
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 17, 2026, 9:47 PM EDT
Not listed Phase 3 Interventional

A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

NCT00005663
View directory record Official record
Conditions
Herpes Simplex, HIV Infections, Herpes Genitalis
Interventions
Valacyclovir hydrochloride
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
20
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of the Vaginal Gel PRO 2000/5

NCT00006207
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 2000
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 17, 2026, 9:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

NCT02707900
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vorinostat, AGS-004
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth

NCT00001007
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Months
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
6
States / cities
Birmingham, Alabama • Stanford, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2008 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

NCT01441063
View directory record Official record
Conditions
Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
Interventions
Zidovudine, Tocilizumab, Valganciclovir (VGC)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 1 Interventional

Effects of BufferGel and PRO 2000/5 Gel in Men

NCT00016536
View directory record Official record
Conditions
HIV Infections
Interventions
Naphthalene 2-sulfonate polymer, Carbopol polymer
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Not applicable Interventional Results available

Learn to Quit-HIV Pilot Study

NCT04609514
View directory record Official record
Conditions
HIV/AIDS, Smoking Cessation, Tobacco Use Disorder
Interventions
Learn to Quit-HIV, QuitGuide, Nicotine patch, Smartphone coaching
Device · Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Not applicable Interventional

Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome

NCT00002112
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Fresno, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:47 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Increasing PrEP With Trans Women in the Deep South

NCT05689281
View directory record Official record
Conditions
Hiv
Interventions
Peer PrEP Navigation
Behavioral
Lead sponsor
CrescentCare
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

NCT01138072
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2248761, Simvastatin, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 17, 2026, 9:47 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People

NCT01904201
View directory record Official record
Conditions
HIV Positive
Interventions
Not listed
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195
View directory record Official record
Conditions
HIV Infections
Interventions
FDA Approved Antiretroviral Therapy (see list below)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 17, 2026, 9:47 PM EDT
Completed No phase listed Observational Results available

HIV and Kidney Function Study

NCT00905151
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Not applicable Interventional

A Study of 1592U89 in HIV-Infected Adults

NCT00002200
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Not applicable Interventional

Text Messaging Intervention to Improve HIV Adherence in Rural Drug Users

NCT01343654
View directory record Official record
Conditions
HIV Infections
Interventions
Text messaging plus EMA, Treatment as usual
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

C2P Mobilization Intervention (Pilot)

NCT00393575
View directory record Official record
Conditions
HIV Infections
Interventions
Community Mobilization
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 17, 2026, 9:47 PM EDT
Terminated Phase 1 Interventional

Study Evaluating Vaccine in Adults With HIV

NCT00195312
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Not applicable Interventional

Reducing Unsafe Alcohol Use in HIV-Positive Individuals

NCT00371969
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Enhanced Motivational Interview, Standard Motivational Interview or viewing DVD
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 2 Interventional

CMV Retinitis Retreatment Trial

NCT00000766
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 17, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

HIV and Fat Accumulation

NCT01088295
View directory record Official record
Conditions
HIV Infection
Interventions
Telmisartan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 17, 2026, 9:47 PM EDT